Cancer Family
Mesenchymal Cell Neoplasm
CI-CAN-00000027Explore in graph →
Non-malignant413 active trials10 approved drugs208 evidence items
- NCIt
- C7059
Loading cancer entity…
Cancer Family
CI-CAN-00000027Explore in graph →
Clinical trials
1,848 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03862885 | Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT04148092 | Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST | approved for marketing | — | — | Deciphera Pharmaceuticals, LLCINDUSTRY | 0 | May 29, 2020 |
| clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2020source: clinicaltrials